Core Points - The article highlights multiple cases of violations of the Central Eight Regulations by health officials in Liaoning Province, including bribery and acceptance of gifts [1][2][3][4] - The ongoing efforts by the Central Commission for Discipline Inspection to address corruption in the medical field are emphasized, with a focus on regulating unethical practices among medical personnel [4][5] Summary by Sections Violations by Health Officials - Dong Guihua, former deputy director of the Shenyang Center for Disease Control, was found guilty of accepting invitations and travel arrangements that could influence his official duties, leading to a three-year prison sentence for bribery [1] - Li Xiaobo, former Party Secretary and Director of the Fuxin Health Bureau, was reported for accepting gifts and money during various holidays and personal events, resulting in his expulsion from the Party and referral for prosecution [2] - Wang Dongdong, former deputy director of the Anshan Medical Security Affairs Service Center, was also found guilty of similar violations, leading to his expulsion and administrative penalties [2] - Wu Changfu, former Party Secretary and Director of Jinzhou Beizhen People's Hospital, was reported for accepting gifts and hosting events improperly, resulting in his expulsion and criminal referral [3] - Guo Dawei, former Party Secretary and Director of Tiaobingshan People's Hospital, was reported for accepting gifts from service objects, leading to his expulsion and criminal referral [3] Broader Context of Corruption in the Medical Field - The article notes that since 2025, local disciplinary inspection agencies have been actively addressing corruption in the medical sector, with a focus on issues such as the acceptance of "red envelopes" and improper benefits disguised as academic exchanges [4] - The Central Commission for Discipline Inspection has been pushing for a nationwide action plan to improve medical ethics and conduct among healthcare professionals, including the introduction of a new code of ethics for medical personnel [4][5]

Policy Developments - The Central Commission for Discipline Inspection and the National Supervisory Commission are intensifying efforts to rectify issues in the pharmaceutical sector, focusing on eliminating practices such as medical staff accepting "red envelopes" and improper benefits through academic exchanges [1] Drug and Device Approvals - YKYY013 injection from Yuyuan Pharmaceutical has received FDA approval for clinical trials aimed at treating chronic hepatitis B virus infection, which utilizes a dual-stranded siRNA mechanism to silence the virus [2] - *ST Suwu's hydrochloride lincomycin injection has passed the consistency evaluation for generic drugs, receiving approval from the National Medical Products Administration [3] - Tianjin Pharmaceutical's recombinant human urokinase (Puyouke) has been granted approval for a new indication for thrombolytic treatment of acute ischemic stroke, expanding its product line in the neurological field [4] Capital Market - Lepu Medical has entered into a strategic cooperation agreement with Hanhai Information Technology, aiming to enhance its medical aesthetics business through shared resources and a comprehensive sales network [5] Industry Events - The National Medical Insurance Administration has published the first batch of typical cases involving violations by designated medical institutions, highlighting issues such as falsifying medical records and duplicate charges [6] - Starting January 1, 2025, a new management system for medical insurance payment qualifications will be implemented, introducing a point-based system for violations to ensure the safety of medical insurance funds [7] Research and Development - Researchers at Kunming University of Science and Technology have successfully constructed an in vitro model of the stomach, providing a new platform for studying human gastric organ development [8] Public Sentiment Alerts - Zhejiang Pharmaceutical announced that its shareholder, Guotou Gaoke, plans to reduce its stake by up to 1% within three months, which will not affect the company's control [9]

持续净化医药领域政治生态和行业生态，是维护人民群众切身利益的必然要求。记者近日从中央纪委国 家监委驻国家卫生健康委纪检监察组了解到，该纪检监察组今年以来加力推进医药领域纠风治乱，督促 综合监督单位重点纠治医务人员收受"红包"、假借学术交流输送利益、利用多点执业损公肥私等问题， 并推动国家卫生健康委研究制定医疗机构工作人员廉洁从业九项准则实施细则，进一步落细有关禁止性 规定，狠刹行业歪风。 "坚持监督、纠风、反腐、治理'四管齐下'，让群众可感可及、得到实惠。"驻国家卫生健康委纪检监察 组有关负责同志介绍，该纪检监察组推动全面梳理党中央关于加强医药卫生领域廉政建设的部署要求， 逐项分解到有关部门，推动明确责任分工，确保重点工作不落空。国家卫生健康委会同教育部、工信部 等部门，聚焦深化医药购销领域治理、系统纠治医疗服务乱象，提出加强穿透监管、强化行业自律、强 化医德医风管理等15项具体举措，明确了医药领域全年纠风工作重点。 纠风工作推进过程中，驻国家卫生健康委纪检监察组通过专题调研等形式，与来自三甲、基层医院的多 名医生进行访谈交流，聚焦突出问题对相关单位提出针对性建议，推动采取有效措施进行整治。比如， 针对医务人 ...